SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Comet MAPS faces a make-or-break moment as it dives toward the sun on April 4 — could it shine in the daytime sky? - 2Public Parks in the USA
- 3Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- 4The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- 5Bennu asteroid samples provide clues about solar system origins and 'space gum'
- US FDA unveils new pathway to approve personalized therapies
- Ever Wonder What An EV Motorcycle Water Crossing Would Be Like? Here You Go
- 6 Solid Moving Administrations for a Calm Movement
- Child influencers helped power a booming industry. It's time for a reckoning.
- Qantas and Virgin Australia Ban Power Bank Usage on Flights Following Safety Incidents
- Remote Headphones: Improve Your Sound Insight
- NASA begins fueling rocket to launch astronauts on the first lunar trip in half a century
- 'War is not over': Detailed diagrams of prisons found in cells of Oct. 7 terrorists
- ICAS calls for clearer safeguards in FRC’s TCA policy
